Details for Patent: 8,658,631
Which drugs does patent 8,658,631 protect, and when does it expire?
Patent 8,658,631 protects XARTEMIS XR and is included in one NDA.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 8,658,631
| Title: | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
| Abstract: | The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof. |
| Inventor(s): | Krishna Devarakonda, Michael J Guiliani, Vishal K Gupta, Ralph A Heasley, Susan Shelby |
| Assignee: | Mallinckrodt LLC |
| Application Number: | US13/473,563 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,658,631 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Device; Dosage form; |
Drugs Protected by US Patent 8,658,631
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,658,631 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
